Pricing database updated August 4, 2026Methodology v1.0How we score →
Compare Providers
Peptides / Best peptide telehealth programs: our standard
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Written by Dr. Parmis Mojarab, DO·Reviewed by Kim Callender, NP, FNP-BC·Published July 12, 2026·Last reviewed August 4, 2026·Methodology v1.0
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

Best peptide telehealth programs: our standard

We do not publish a peptide provider ranking built on marketing claims. This page explains the standard a peptide program must meet to earn a recommendation, and links to the verification tools.

Quick answer

A recommendable peptide program requires licensed clinician oversight, a licensed dispensing pharmacy, honest regulatory disclosure, and evidence-based claims. Until providers clear that bar with verified evidence, we publish the standard rather than a ranking.

Where should you read next?

Verify a peptide provider

Checklist

Peptide therapy overview

How it works

Tesamorelin

An FDA-approved peptide

Sources

  1. U.S. Food and Drug Administration — approval and compounding status.
  2. Primary clinical literature cited on child pages.
  3. Our methodology and source standards.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices — NovoCare and LillyDirect — were re-read on the manufacturers’ own published price guides on 4 August 2026. Figures captured from third-party provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row says so. We do not restamp a figure we have not re-read.